Lilly will leverage the Aqua tool in more therapeutic programs, and HistoRx will work on customized assays.
Eli Lilly has gained broader use of HistoRx’ tissue biomarker analysis technology through a three-year extension. The expanded deal allows Lilly to increase its use of the Aqua® platform beyond the specified programs detailed in the 2005 agreement.
Under the new alliance, HistoRx will also develop customized Aqua analysis-based immunohistochemical assays for Lilly to use in drug discovery and development projects.
HistoRx has the option to commercialize the assays and reagents developed during the course of the partnership for clinical use as predictive diagnostics.